Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer

Chemotherapy

Volumn 57, Issue 2, 2011, Pages 147-155

  Chung, Fu Tsai ^a   Lee, Kang Yun ^a   Fang, Yueh Fu ^a   Shieh, Meng Heng ^a   Lin, Shu Min ^a   Yu, Chih Teng ^a   Lo, Yun Lun ^a   Lin, Ting Yu ^a   Kuo, Chih Hsi ^a   Feng, Po Hao ^a   Ni, Yung Lun ^a   Kuo, Han Pin ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Advanced non small cell lung cancer; Docetaxel; Pemetrexed

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; FOLIC ACID; GEFITINIB; GRANULOCYTE COLONY STIMULATING FACTOR; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RETROSPECTIVE STUDY; SENSORY DYSFUNCTION; SINGLE DRUG DOSE; THROMBOCYTOPENIA; UNIVERSITY HOSPITAL;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 79953215730     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321037     Document Type: Article

References (30)

1. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA, Johnson BE: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001; 19: 1734-1742. (Pubitemid 32230875)
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98. (Pubitemid 34438899)
3. Johnson DH: Locally advanced, unresectable non-small cell lung cancer: new treatment strategies. Chest 2000; 117: 123S-126S. (Pubitemid 30225151)
4. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103. (Pubitemid 30324363)
5. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in patients with nonsmall- cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597. (Pubitemid 41079796)
6. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818.
7. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354-2362. (Pubitemid 30415821)
8. Di Maio M, Perrone F, Chiodini P, Gallo C, Camps C, Schuette W, Quoix E, Tsai CM, Gridelli C: Individual patient data metaanalysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced nonsmall- cell lung cancer. J Clin Oncol 2007; 25: 1377-1382. (Pubitemid 46706885)
9. Takigawa N, Segawa Y, Kishino D, Fujiwara K, Tokuda Y, Seki N, Shinkai T, Watanabe Y, Hiraki S, Kozuki T, Gemba K, Tabata M, Kiura K, Ueoka H, Tanimoto M: Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients. Cancer Chemother Pharmacol 2004; 54: 230-236. (Pubitemid 39141739)
10. Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, Salvagni S, Piantedosi FV, Palazzolo G, Caffo O, Ceribelli A, Falcone A, Mazzanti P, Brancaccio L, Capuano MA, Isa L, Barbera S, Perrone F: A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004; 91: 1996-2004. (Pubitemid 40128765)
11. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M: Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005; 23: 8389-8395.
12. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T: Phase II trial of docetaxel in previously untreated advanced nonsmall- cell lung cancer: a Japanese cooperative study. J Clin Oncol 1996; 14: 1649-1655.
13. Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J: A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naive non-small-cell lung cancer in Taiwan. Lung Cancer 2007; 56: 363-369. (Pubitemid 46679082)
14. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M: Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008; 26: 4244-4252.
15. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, Seto T, Ando M, Satoh T, Yoshimura N, Negoro S, Fukuoka M: Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced nonsmall- cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006; 24: 3657-3663. (Pubitemid 46630541)
16. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181. (Pubitemid 36962641)
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
18. Wildi JD, Baggstrom MQ, Suresh R, Read W, Fracasso PM, Govindan R: A phase I study of docetaxel and bexarotene. Chemotherapy 2008; 54: 125-130. (Pubitemid 351448599)
19. Dragnev KH, Hardin SB, Pipas JM, Davis TH, Rigas JR: A Dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors. Chemotherapy 2010; 56: 135-141.
20. Taguchi T, Nakayama T, Masuda N, Yoshidome K, Akagi K, Nishida Y, Yoshikawa Y, Ogino N, Abe C, Sakamoto J, Noguchi S, Kinki Breast Cancer Study Group: Study of low-dose capecitabine monotherapy for metastatic breast cancer. Chemotherapy 2010; 56: 166-170.
21. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, Heelan RT: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994; 12: 1232-1237.
22. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage nonsmall- cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
23. Camps C, Massuti B, Jimenez A, Maestu I, Gomez RG, Isla D, Gonzalez JL, Almenar D, Blasco A, Rosell R, Carrato A, Vinolas N, Batista N, Giron CG, Galan A, Lopez M, Blanco R, Provencio M, Diz P, Felip E: Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-smallcell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006; 17: 467-472. (Pubitemid 43329585)
24. Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J: A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006; 129: 1031-1038.
25. Bria E, Cuppone F, Ciccarese M, Nistico C, Facciolo F, Milella M, Izzo F, Terzoli E, Cognetti F, Giannarelli D: Weekly docetaxel as second line chemotherapy for advanced nonsmall- cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 2006; 32: 583-587. (Pubitemid 44645022)
26. Lai CL, Tsai CM, Chiu CH, Wang GS, Su WJ, Chen YM, Perng RP: Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Jpn J Clin Oncol 2005; 35: 700-706.
27. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA: The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009; 14: 253-263.
28. Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y, Saijo N, Fukuoka M: Efficacy and safety of two doses of pemetrexed suppl.emented with folic acid and vitamin B 12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008; 14: 4206-4212.
29. Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H: Expression of ERCC1 and class III beta-tubulin in nonsmall cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009; 64: 326-333.
30. Seve P, Isaac S, Tredan O, Souquet PJ, Pacheco Y, Perol M, Lafanechere L, Penet A, Peiller EL, Dumontet C: Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005; 11: 5481-5486. (Pubitemid 41060824)